Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

TV, the nation's leading Spanish-language public broadcaster, is proud to announce a partnership with South Florida PBS to ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0615 ET – Merck KGaA expects its 2024 sales target to come in ...

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Render of the proposed superyacht Ulyssia with construction to start in northern Germany in March. “There will definitely be ...

Merck, which previously predicted 2024 sales of between 20. ... useful and valuable Life Sciences service that brings ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...